MedTrace Logo

"Hepatic Substrate Flux Rates in Type 2 Diabetes"

NCT04088851 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-01-13

No results posted yet for this study

Summary

Investigation of the effects of redox shuttle inhibition by metformin on gluconeogenic flux rates of lactate and glycerol in humans with type 2 diabetes

Conditions

Interventions

DRUG

On Metformin

Oral intake of Metformin (1 g / day) for 2 weeks

DRUG

Off Metformin

No oral intake of Metformin (1 g / day) for 2 weeks

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • German Diabetes Center

    lead OTHER

Principal Investigators

  • Michael Roden, Prof., MD · German Diabetes Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-11
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04088851 on ClinicalTrials.gov